CRISPR Therapeutics AG
CRSP
$41.86
$3.298.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 865.00K | 35.69M | 602.00K | 517.00K | 504.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 865.00K | 35.69M | 602.00K | 517.00K | 504.00K |
| Cost of Revenue | 129.99M | 82.16M | 93.31M | 132.30M | 123.14M |
| Gross Profit | -129.13M | -46.46M | -92.71M | -131.78M | -122.63M |
| SG&A Expenses | 19.30M | 18.12M | 17.42M | 19.48M | 17.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 149.29M | 100.28M | 110.73M | 151.78M | 141.09M |
| Operating Income | -148.42M | -64.59M | -110.13M | -151.26M | -140.59M |
| Income Before Tax | -134.89M | -36.61M | -85.07M | -125.12M | -115.87M |
| Income Tax Expenses | 1.11M | 700.00K | 876.00K | 1.29M | 724.00K |
| Earnings from Continuing Operations | -136.00M | -37.31M | -85.94M | -126.41M | -116.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.00M | -37.31M | -85.94M | -126.41M | -116.59M |
| EBIT | -148.42M | -64.59M | -110.13M | -151.26M | -140.59M |
| EBITDA | -143.69M | -59.75M | -105.39M | -146.42M | -135.75M |
| EPS Basic | -1.58 | -0.44 | -1.01 | -1.49 | -1.43 |
| Normalized Basic EPS | -0.98 | -0.27 | -0.62 | -0.92 | -0.89 |
| EPS Diluted | -1.58 | -0.44 | -1.01 | -1.49 | -1.43 |
| Normalized Diluted EPS | -0.98 | -0.27 | -0.62 | -0.92 | -0.89 |
| Average Basic Shares Outstanding | 85.94M | 85.46M | 85.23M | 84.92M | 81.79M |
| Average Diluted Shares Outstanding | 85.94M | 85.46M | 85.23M | 84.92M | 81.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |